Epilepsy
PRAX-562
Program Detail
Tackling movement disorders through 2 mechanisms of action. PRAX-562 is in development for the treatment of early-onset developmental and epileptic encephalopathies (DEEs) due to variants in SCN2A, SCN8A, and for additional DEEs, and rare epilepsies.
PRAX-562 : Introduction
DEEs not only include severe, early-onset seizures, which can be life-threatening, but also developmental and intellectual disability. All of these symptoms have a significant impact on quality of life for children and their caregivers. There is no effective treatment.
PRAX-562 has the potential to provide best-in-class seizure control with reduced treatment burden for patients living with scn2a, scn8a, other DEEs, and other rare epilepsies.
Selective regulation of the persistent sodium current, for precise control of sodium channel hyperexcitability.
Best-in-class seizure control with unprecedented tolerability.
Convenient auto-titration regimen with stable pharmacokinetics.
Mechanism of action
Voltage-gate sodium channels (NaV) are the key arbiters of neuronal excitability in the CNS. Persistent sodium current is a critical driver of pathological hyperexcitability in epilepsy.
Key Upcoming Milestones
Next steps for PRAX-222 Clinical Program
Medical Papers + Presentations
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Science Paper
Add Your Heading Text Here
Science Paper
Add Your Heading Text Here
Science Paper
